Pricing Log in Create free account

Spyre Therapeutics, Inc. (SYRE) vs TG Therapeutics, Inc. (TGTX)

Spyre Therapeutics, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Spyre Therapeutics, Inc. and TG Therapeutics, Inc. are of similar size ($9.2B and $8.9B). Spyre Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 19.1×. TG Therapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against −81.8%. TG Therapeutics, Inc. has the higher net margin (55.2% vs 0.00%) and the higher return on invested capital (10.7% vs 0.00%). Across the 18 metrics below, TG Therapeutics, Inc. leads on 14 and Spyre Therapeutics, Inc. on 4.

Valuation

Metric SYRE TGTX Biotechnology median
P/E n/m 19.11 10.26
P/S 8,159.98 10.30 9.18
P/B 9.50 13.64 2.05
Price to free cash flow n/m 473.79 24.81
EV/EBITDA n/m 62.00 0.65
EV/Sales 7,142.99 10.54 8.98
Earnings yield (3.16%) 5.23% (34.89%)
Free cash flow yield (2.89%) 0.21% (24.52%)

Profitability

Metric SYRE TGTX Biotechnology median
Gross margin 100.00% 82.37% 65.16%
Operating margin 0.00% 17.05% 0.00%
Net margin 0.00% 55.22% 0.00%
Free cash flow margin 0.00% 2.17% 0.00%
Return on equity (41.15%) 100.28% (50.12%)
Return on assets (30.89%) 37.70% (45.60%)
Return on invested capital 0.00% 10.69% 0.00%

Growth

Metric SYRE TGTX Biotechnology median
Revenue growth (TTM) (81.84%) 76.08% 6.26%
EPS growth (last fiscal year) 55.24% 1,746.67% 29.88%
Revenue growth, 5-year CAGR (28.15%) 426.73% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SYRE TGTX Biotechnology median
Debt to equity 0.00 1.23 0.00
Current ratio 27.40 4.27 4.89
Net debt to EBITDA 3.61 0.86 1.01

Dividend

Metric SYRE TGTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric SYRE TGTX Biotechnology median
Market cap 9.17b 8.87b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack